To qualify for treatment with omalizumab, patients also must have a positive skin test (IgE level between 30 IU per mL and 700 IU per mL) or in vitro reactivity to a perennial inhaled allergen and their asthma should be uncontrolled with inhaled oral corticosteroids. 1 Inhaled corticosteroids should not be abruptly stopped at initiation of omalizumab treatment. The usual dosage of omalizumab is 150 to 375 mg subcutaneously every 2 or 4 weeks, based on patient weight and serum total IgE level (measured before treatment is started). The drug should be administered in the office to observe the patient for anaphylaxis. Effectiveness is monitored via symptom response.
The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands .   This product was eventually discontinued and replaced in the United States with a new product named Oxandrin, which is the sole remaining brand name for oxandrolone in the United States.   Oxandrolone has also been sold under the brand names Antitriol ( Spain ), Anatrophill ( France ), Lipidex ( Brazil ), Lonavar ( Argentina , Australia , Italy ), Protivar, and Vasorome ( Japan ) among others.     Additional brand names exist for products that are manufactured for the steroid black market.